Since the discovery of insulin almost 100 years ago, there has been no novel therapy introduced for Type 1 diabetes. That could change in the coming months, however, if the overlooked – and undervalued – biotech highlighted in today’s article receives FDA approval for the use of its Type 1 diabetes delaying drug in at-risk populations – something that appears to be highly likely. For more on what the author sees as an attractive buying opportunity, CLICK HERE.